| Autor: |
Haratake, Naoki, Ozawa, Hiroki, Morimoto, Yoshihiro, Yamashita, Nami, Daimon, Tatsuaki, Bhattacharya, Atrayee, Wang, Keyi, Nakashoji, Ayako, Isozaki, Hideko, Shimokawa, Mototsugu, Kikutake, Chie, Suyama, Mikita, Hashinokuchi, Asato, Takada, Kazuki, Takenaka, Tomoyoshi, Yoshizumi, Tomoharu, Mitsudomi, Tetsuya, Hata, Aaron N., Kufe, Donald |
| Zdroj: |
Journal of Thoracic Oncology; 20230101, Issue: Preprints |
| Abstrakt: |
Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional EGFR mutations, MET amplification and other pathways. There is no known involvement of the oncogenic MUC1-C protein in acquired osimertinib resistance. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
